| Literature DB >> 34456874 |
Lisa H de Vries1, Dilay Aykan1, Lutske Lodewijk1, Johanna A A Damen2, Inne H M Borel Rinkes1, Menno R Vriens1.
Abstract
Purpose: Conventional thyroidectomy has been standard of care for surgical thyroid nodules. For cosmetic purposes different minimally invasive and remote-access surgical approaches have been developed. At present, the most used robotic and endoscopic thyroidectomy approaches are minimally invasive video assisted thyroidectomy (MIVAT), bilateral axillo-breast approach endoscopic thyroidectomy (BABA-ET), bilateral axillo-breast approach robotic thyroidectomy (BABA-RT), transoral endoscopic thyroidectomy via vestibular approach (TOETVA), retro-auricular endoscopic thyroidectomy (RA-ET), retro-auricular robotic thyroidectomy (RA-RT), gasless transaxillary endoscopic thyroidectomy (GTET) and robot assisted transaxillary surgery (RATS). The purpose of this systematic review was to evaluate whether minimally invasive techniques are not inferior to conventional thyroidectomy.Entities:
Keywords: bilateral axillo-breast approach endoscopic thyroidectomy (BABA-ET); bilateral axillo-breast approach robotic thyroidectomy (BABA-RT); gasless transaxillary endoscopic thyroidectomy (GTET); minimally invasive video assisted thyroidectomy (MIVAT); retro-auricular endoscopic thyroidectomy (RA-ET); retro-auricular robotic thyroidectomy (RA-RT); robot assisted transaxillary surgery (RATS); transoral endoscopic thyroidectomy via vestibular approach (TOETVA)
Mesh:
Year: 2021 PMID: 34456874 PMCID: PMC8387875 DOI: 10.3389/fendo.2021.719397
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Preoperatively marked patients who will undergo (A) TOETVA (7). Three incisions will be made in the oral vestibule, one for the camera and two laterally for dissection and coagulation instruments; and (B) RATS (8). The incision site is marked laterally. The dotted lines mark the borders of the surgical working space.
Figure 2Flowchart of study selection using PRISMA 2020 flow diagram.
Operating time and length of hospital stay.
| A. | Median | Minimum | Q1 | Q3 | Maximum | IQR | No. of patients |
|---|---|---|---|---|---|---|---|
|
| |||||||
| BABA-ET ( | 154.2 | 109.3 | 128.9 | 165.3 | 238.2 | 36.4 | 1,416 |
| BABA-RT ( | 190.5 | 118.8 | 165.1 | 206.0 | 290.6 | 40.9 | 1,169 |
| MIVAT ( | 74.3 | 41.0 | 66.4 | 91.3 | 222.5 | 24.9 | 3,463 |
| TOETVA ( | 152.0 | 97.0 | 121.0 | 196.1 | 216.7 | 75.1 | 590 |
| RA-ET ( | 143.0 | 123.4 | 127.2 | 148.5 | 152.0 | 21.3 | 89 |
| RA-RT ( | 179.1 | 167.1 | NA | NA | 191.0 | NA | 55 |
| GTET ( | 166.8 | 129.8 | 140.6 | 189.1 | 297.5 | 48.6 | 882 |
| RATS ( | 141.5 | 101.1 | 123.2 | 178.0 | 232.0 | 54.8 | 13,357 |
| Standard of care ( | 105.5 | 70.8 | 86.1 | 123.5 | 156.2 | 37.4 | 2,150 |
|
|
|
|
|
|
|
|
|
|
| |||||||
| BABA-ET ( | 3.1 | 2.5 | 3.0 | 4.3 | 6.9 | 1.3 | 1,353 |
| BABA-RT ( | 3.6 | 2.9 | 3.2 | 4.0 | 5.1 | 0.8 | 1,256 |
| MIVAT ( | 1.9 | 0.0 | 1.4 | 2.7 | 4.7 | 1.3 | 2,937 |
| TOETVA ( | 3.6 | 0.8 | 2.3 | 4.3 | 5.4 | 2.0 | 740 |
| RA-ET ( | 4.5 | 2.5 | 3.2 | 5.6 | 5.9 | 2.4 | 84 |
| RA-RT ( | NA | NA | NA | NA | NA | NA | 0 |
| GTET ( | 3.4 | 2.2 | 2.6 | 5.0 | 6.5 | 2.4 | 1,167 |
| RATS ( | 2.9 | 0.0 | 1.2 | 3.3 | 5.1 | 2.1 | 14,232 |
| Standard of care ( | 3.1 | 0.0 | 1.0 | 3.6 | 5.5 | 2.6 | 2,250 |
Q1, first quartile; Q3, third quartile; IQR, interquartile range; NA, not applicable.
Figure 3Forest plots of operating time for (A) BABA-ET, (B) BABA-RT, (C) MIVAT lobectomy, (D) MIVAT total thyroidectomy, (E) TOETVA, (F) GTET and (G) RATS.
Figure 4Forests plots of hospital stay for (A) BABA-ET, (B) BABA-RT, (C) MIVAT, (D) TOETVA, (E) GTET and (F) RATS.
Incidence of recurrent laryngeal nerve injury.
| A. | Median | Minimum | Q1 | Q3 | Maximum | IQR | No. of cases | No. of patients |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| BABA-ET ( | 3.7 | 0.0 | 1.4 | 7.3 | 28.0 | 5.9 | 162 | 1,491 |
| BABA-RT ( | 3.0 | 0.0 | 2.0 | 6.4 | 19.0 | 4.4 | 77 | 1,554 |
| MIVAT ( | 2.5 | 0.0 | 1.7 | 4.2 | 17.0 | 2.5 | 86 | 1,727 |
| TOETVA ( | 4.0 | 0.0 | 3.1 | 7.1 | 12.5 | 4.0 | 32 | 736 |
| RA-ET ( | 1.1 | 0.0 | 0 | 6.6 | 11.1 | 6.6 | 3 | 84 |
| RA-RT ( | 5.0 | NA | NA | NA | NA | NA | 1 | 20 |
| GTET ( | 5.3 | 0.0 | 3.1 | 6.3 | 15.0 | 3.2 | 85 | 1,921 |
| RATS ( | 3.3 | 0.0 | 1.8 | 6.0 | 20.5 | 4.2 | 456 | 15,780 |
| Standard of care ( | 3.3 | 0.0 | 0.0 | 8.8 | 19.5 | 8.8 | 172 | 2,908 |
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| BABA-ET ( | 0.0 | 0.0 | 0.0 | 2.1 | 4.3 | 2.1 | 15 | 1,385 |
| BABA-RT ( | 0.0 | 0.0 | 0.0 | 0.7 | 0.9 | 0.7 | 5 | 1,554 |
| MIVAT ( | 0.0 | 0.0 | 0.0 | 1.5 | 2.9 | 1.5 | 45 | 4,129 |
| TOETVA ( | 0.0 | 0.0 | 0.0 | 1.1 | 3.1 | 1.1 | 6 | 756 |
| RA-ET ( | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 84 |
| RA-RT ( | 0.0 | NA | NA | NA | NA | NA | 0 | 20 |
| GTET ( | 0.4 | 0.0 | 0.0 | 1.6 | 6.3 | 1.6 | 11 | 2,033 |
| RATS ( | 0.1 | 0.0 | 0.0 | 0.5 | 1.3 | 0.5 | 59 | 15,756 |
| Standard of care ( | 0.4 | 0.0 | 0.0 | 0.9 | 4.0 | 0.9 | 26 | 2,970 |
Q1, first quartile; Q3, third quartile; IQR, interquartile range; NA, not applicable.
Figure 5Forests plots of transient recurrent laryngeal nerve injury for (A) BABA-ET, (B) BABA-RT, (C) MIVAT, (D) TOETVA, (E) GTET and (F) RATS.
Figure 6Forests plots of permanent recurrent laryngeal nerve injury for (A) BABA-ET, (B) BABA-RT, (C) MIVAT, (D) TOETVA, (E) GTET and (F) RATS.
Incidence of hypocalcemia.
| A. | Median | Minimum | Q1 | Q3 | Maximum | IQR | No. of cases | No. of patients |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| BABA-ET ( | 14.0 | 0.0 | 3.3 | 28.2 | 46.2 | 24.9 | 259 | 1,208 |
| BABA-RT ( | 21.6 | 2.8 | 10.8 | 31.7 | 38.6 | 20.9 | 283 | 1,171 |
| MIVAT ( | 5.6 | 0.0 | 3.0 | 10.0 | 23.4 | 7.0 | 231 | 3,588 |
| TOETVA ( | 7.1 | 0.0 | 4.0 | 21.3 | 50.0 | 17.3 | 64 | 644 |
| RA-ET ( | 0.0 | 0.0 | 0.0 | 2.8 | 5.8 | 2.8 | 1 | 84 |
| RA-RT ( | 33.3 | NA | NA | NA | NA | NA | 1 | 3 |
| GTET ( | 3.3 | 0.0 | 0.0 | 26.7 | 33.3 | 26.7 | 95 | 1,020 |
| RATS ( | 18.4 | 0.0 | 8.3 | 39.9 | 51.7 | 31.7 | 2,239 | 7,002 |
| Standard of care ( | 17.1 | 0.0 | 4.5 | 34.0 | 44.6 | 29.5 | 631 | 3,157 |
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| BABA-ET ( | 1.3 | 0.0 | 0.0 | 2.1 | 4.2 | 2.1 | 25 | 1,048 |
| BABA-RT ( | 0.9 | 0.0 | 0.0 | 1.7 | 4.8 | 1.7 | 13 | 1,171 |
| MIVAT ( | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | 23 | 3,402 |
| TOETVA ( | 0.0 | 0.0 | 0.0 | 0.7 | 5.0 | 0.7 | 2 | 644 |
| RA-ET ( | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 84 |
| RA-RT ( | 0.0 | NA | NA | NA | NA | NA | 0 | 3 |
| GTET ( | 0.0 | 0.0 | 0.0 | 0.7 | 2.7 | 0.7 | 4 | 1,020 |
| RATS ( | 0.0 | 0.0 | 0.0 | 0.1 | 3.1 | 0.1 | 45 | 6,986 |
| Standard of care ( | 1.5 | 0.0 | 0.0 | 3.2 | 6.7 | 3.2 | 57 | 3,024 |
Q1, first quartile; Q3, third quartile; IQR, interquartile range; NA, not applicable.
Figure 7Forests plots of transient hypocalcemia for (A) BABA-ET, (B) BABA-RT, (C) MIVAT, (D) TOETVA, (E) GTET and (F) RATS.
Figure 8Forests plots of permanent hypocalcemia for (A) BABA-ET, (B) BABA-RT, (C) MIVAT, (D) TOETVA, (E) GTET and (F) RATS.